ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted pill shows promise in Gene-Matched tumors
Disease control CompletedThis study tested a drug called tazemetostat in 20 children and teens whose cancers had come back or didn't respond to treatment. Only those with specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors were included. The goal was to see if the drug could shrink tumors o…
Matched conditions: ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug shows promise for kids with recurrent cancers
Disease control CompletedThis study tested a drug called samotolisib in 18 children whose cancers had come back or didn't respond to treatment. The children had specific gene changes in their tumors. The goal was to see if the drug could shrink or stop the cancer. The study was completed, but results are…
Matched conditions: ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC